Abstract: Endometrial stromal sarcoma (ESS) is a genetically heterogenous group of uterine sarcomas, of which almost half are associated with JAZF1 rearrangement. We recently identified a novel genetic fusion between YWHAE and FAM22A/B in ESS harboring t(10;17)(q22;p13) and herein describe the clinicopathologic features of 13 YWHAE-FAM22 ESS cases (11 primary and 3 metastatic) and compare them with 20 ESS cases with JAZF1 rearrangement. Ten of 11 primary uterine tumors contained morphologically high-grade areas composed of round cells arranged in nests with a delicate stromal capillary network. The tumor cells showed large nuclei with irregular nuclear contours and significant mitotic activity (> 10 mitoses/10 HPF) in addition to focal tumor necrosis, in contrast to JAZF1 ESS, which lacked a nested growth pattern, were composed of cells with small round/oval nuclei, and typically had < 5 MF/ 10 HPF. In 7 of the 11 uterine tumors, there was an additional cytologically bland and mitotically weakly active spindle cell component with a fibrous/fibromyxoid stroma (ESS, fibromyxoid variant). Two metastatic tumors (pulmonary) also contained round cell and spindle cell components, whereas 1 metastasis (vaginal) was composed solely of the spindle cell component. In both primary and metastatic tumors, the spindle cells were diffusely positive for estrogen and progesterone receptors and CD10, in contrast to the round cell areas, which were negative. Clinically, 10 of 12 patients with YWHAE-FAM22 ESS presented with FIGO stages II to III disease, in contrast to only 4 of 16 patients with JAZF1 ESS presenting with stages II to III disease (P < 0.05). Tumors with YWHAE-FAM22 rearrangements constitute a distinct group of ESS, which is associated with high-grade morphology and aggressive clinical behavior compared to JAZF1 ESS. Thus, their distinction from typical JAZF1 ESS is important for prognostic and therapeutic purposes.
ndometrial stromal sarcoma (ESS) is the second most common malignant uterine mesenchymal tumor, and it affects women primarily in the perimenopausal age group. These tumors are composed of cells that morphologically resemble non-neoplastic proliferative-phase endometrial stroma and have been termed "low-grade ESS" according to the current WHO classification to reflect their highly differentiated state. Classically, the tumor cells have bland nuclear features with monotonous oval to spindle cells concentrically proliferating around a rich vascular network of arterioles and capillaries; mitotic activity is typically low (< 5 per 10 HPF), and tumor necrosis is absent in most tumors. 8, 9, 31 The WHO also recognizes another category of malignant stromal neoplasia, termed undifferentiated endometrial sarcoma (UES). In contrast to low-grade ESS, UES by definition does not resemble endometrial stroma; instead, it exhibits high-grade cytologic atypia with marked nuclear pleomorphism accompanied in most instances by a high mitotic rate and the presence of tumor necrosis. Distinction between ESS and UES is crucial because of major differences in prognosis between these 2 tumor types (5 y survival approximately 85% in ESS vs. < 50% in UES patients). 8, 2, 5, 7, [11] [12] [13] In recent years it has become increasingly clear that this binary classification scheme does not adequately reflect the morphologic diversity that can occur in malignant stromal tumors. For example, some uterine sarcomas can display cytologic and immunohistochemical features that are intermediate between classic low-grade ESS and UES, which has been described in the literature as UES with nuclear uniformity. 20 Moreover, other tumors may show areas of UES juxtaposed to low-grade areas. In both instances, however, tumors behave in a more aggressive manner compared with classic low-grade ESS. In addition to high-grade cytologic features, ESS can also display variant histologic appearances, including smooth muscle, sex cord, glandular, and fibrous differentiation. 31 In keeping with the varied histologic appearance, ESS as currently defined is genetically heterogenous as well. 38 Even though approximately 50% to 60% of ESS cases demonstrate a rearrangement of genes involved in chromatin binding (JAZF1, SUZ12, PHF1, EPC1), most commonly in the form of t(7;17)(p15;q21), which results in JAZF1-SUZ12 genetic fusion, 20, 10, 15, 16, 19, 27, 28, 32 little is known about the genetics of the remaining tumors. ESS harboring t(7;17) and JAZF1-SUZ12 genetic fusion tends to display a classic lowgrade morphology, including variants. 16 Although rare cases of ESS harboring JAZF1 rearrangement can show highergrade histologic features at initial presentation, 20 these tend to be observed in recurrent tumors, 4, 30 and the genetics of a significant subset of ESS, especially ones with higher-grade histologic features, remain undefined.
We recently identified the genes rearranged in t(10;17)(q22;p13), a recurrent aberration previously reported in ESS 3, 24, 28, 37 and in a subset of clear cell sarcoma of the kidney, 6, 35, 36 and the rearrangement results in an in-frame fusion between YWHAE (exons 1 to 5) and 1 of the 2 highly homologous genes FAM22A and FAM22B (exons 2 to 7) (designated as YWHAE-FAM22). 23 The goal of this study is to report the clinical and histopathologic features of primary and metastatic ESS associated with YWHAE-FAM22 rearrangements.
METHODS

Tumor Samples
Formalin-fixed paraffin-embedded tumor tissues from 13 ESS with YWHAE-FAM22 rearrangement and 20 molecularly confirmed JAZF1-rearranged ESS were obtained from the pathology archives at Brigham and Women's Hospital (BWH), Catholic University of Leuven (KUL), Massachusetts General Hospital (MGH), and Vancouver General Hospital (VGH). The histologic features of all tumors were reviewed by 2 authors (C.H.L. and M.R.N.). The study has been approved by the respective Institutional Review Boards.
Fluorescence In Situ Hybridization (FISH)
FISH probes flanking genes of interest (YWHAE, FAM22A, and FAM22B) shown in supplemental Figure 1 , Supplemental Digital Content 1, http://links.lww.com/PAS/ A112, were prepared from BAC clones (CHORI). FISH was performed on 4-mm-thick full sections and tissue microarray sections using a standard pretreatment and hybridization protocol. 25 The slides were reviewed manually with at least 50 tumor nuclei evaluated for each case, and a cutoff of > 30% nuclei showing a split signal was used to be considered positive for rearrangement of the flanked gene (supplemental Figure 1 , Supplemental Digital Content 1, http://links.lww.com/PAS/A112). Normal paired signals are defined as an orange and green signal less than 3 signal diameters apart or as a single yellow (overlapping) signal, whereas unpaired signals are those separated by Z3 signal diameters. For tissue microarray sections, all cores with complete or partial loss of tumor tissue ( < 50 tumor nuclei) or with weak signals were excluded from the analysis. To be considered positive for YWHAE-FAM22A/B rearrangement, an individual case needs to demonstrate concomitant rearrangement in YWHAE and FAM22A or in YWHAE and FAM22B by FISH analysis.
Immunohistochemistry
Immunohistochemical analysis was performed on whole sections of the 11 primary YWHAE-FAM22 ESS and 2 metastatic YWHAE-FAM22 ESS cases. Estrogen receptor (ER, Thermo Fisher, SP1, 1:60 dilution, citrate buffer pressure cook), progesterone receptor (PR, Dako, PGR636, 1:200 dilution, citrate buffer pressure cook), and CD10 (Vector lab, 56C6, 1:10 dilution, citrate buffer pressure cook) immunostaining was performed according to the manufacturer's recommendations using the EnVision+ System-HRP (Dako) on an automated instrument (Dako Autostainer Plus, Dako). For Ki-67 (Labvision, clone SP6, 1:200 dilution), antigen retrieval was performed using CC1 antigen retrieval buffer (Ventana Medical Systems, AZ). For ER and PR, moderate to strong nuclear staining in > 5% of tumor cells was considered positive. For CD10, moderate to strong cytoplasmic staining in > 30% of tumor cells was considered positive. Ki-67 staining was evaluated manually on the basis of assessment of 100 tumor cell nuclei in representative areas.
RESULTS
Clinical Features of ESS With YWHAE-FAM22 and Comparison with JAZF1-rearranged ESS
A total of 13 primary and/or metastatic uterine sarcomas were found to harbor YWHAE and FAM22A/B genetic rearrangement by FISH analysis (Table 1 and supplemental Figure 1 , Supplemental Digital Content 1, http://links.lww.com/PAS/A112). The 13 patients ranged in age from 28 to 67 (mean 50) years at the time of initial diagnosis ( Table 1 ). The most common presenting symptom for patients with uterine YWHAE-FAM22 ESS was abnormal vaginal bleeding (menorrhagia or peri/ postmenopausal bleeding). Staging information was available for 12 of 13 patients (Table 1) . By the most recent FIGO staging criteria (2009), 10 of 12 (83%) patients presented with stages II to III disease (stages III to IV disease by the former FIGO stating criteria), where there is evidence of extrauterine tumor extension. Of the 2 patients with FIGO stage I tumors at presentation, 1 developed pulmonary metastases a year later, and she is alive with disease 5 years after the initial diagnosis, whereas the other patient developed multiple peritoneal recurrences a year later and is alive with disease 1.5 years after the initial diagnosis.
Clinical follow-up (at least 1 y with an average of 3.5 y) information was available for 10 patients (Table 1) . Two died from progressive disease 2 years later, and 7 patients were alive with disease (ranging from 1 to 10 y) after the initial diagnosis. The latter had a combination of pelvic/peritoneal and/or distant recurrence (pulmonary metastases in 4 patients). Only 1 patient had no evidence of disease with a follow-up of 3.75 years; she originally presented with stage IIIB ESS and underwent total abdominal hysterectomy and bilateral salpingo-oophorectomy with pelvic/peritoneal tumor debulking followed by 5 cycles of chemotherapy (adriamycin and ifosfamide with mesna support). All of the patients were treated surgically with total hysterectomy and adnexectomy (+/À pelvic/peritoneal tumor debulking) for the primary disease.
Staging data were available for 16 of 20 patients with JAZF1-rearranged ESS, and only 4 of 16 (25%) had FIGO 2009 stages II to III disease (stages III to IV disease by former FIGO staging criteria). Follow-up information was available for 17 of 20 patients with JAZF1-rearranged ESS. Among these 17 patients, 13 (76%) were alive and well (follow-up period ranging from 1 to 34 y, average 10 y), 2 were alive with disease, whereas 2 died of the disease (within a month and 9 y after the initial diagnosis, respectively).
Histopathologic Features of ESS Harboring YWHAE-FAM22 Genetic Fusion and Comparison with JAZF1-rearranged ESS
The primary site for all 13 YWHAE-FAM22 ESS cases was the uterine corpus ( Fig. 1) . The uterine tumors ranged in size from 3 to 9 (median 7.5) cm (Table 2 ). It is [20] .
YWHAE-FAM22B
Stage IIIC AWD (1 y) noteworthy that 1 ESS with bulky retroperitoneal tumor (measuring approximately 27 cm) showed a 1 cm tumor in the endometrial cavity. In 11 of 13 cases, the primary tumor was available for histologic review (1 with both primary and pulmonary metastases), whereas only metastatic tumor was available for review in the 2 remaining cases. Within the uterus, all YWHAE-FAM22 ESS cases showed extensive permeative growth through the myometrium (similar to that seen in JAZF1-rearranged ESS), with invasion well into the outer half of the myometrium (Figs. 2A, B) . Vascular invasion was present in all cases. Of the 11 primary uterine tumors, 7 contained a mixture of round cell and spindle cell areas, whereas 3 and 1 showed a purely round cell and purely spindle cell appearance, respectively (Table 2) . YWHAE-FAM22 genetic rearrangement was demonstrated by FISH in both the round cell and spindle cell areas in tumors showing a mixture of the 2 components. The round cell component was highly cellular, and the tumor cells were typically arranged in a vaguely nested growth pattern (Figs. 2C-F) , with the nests being separated by a delicate stromal capillary network. These cohesive round cells had scanty (small round blue cell appearance; Figs. 2D, F) to moderate eosinophilic (epithelioid appearance) cytoplasm (Figs. 2C, E) . The round cell component showed no significant pleomorphism in nuclear size on low-power (Â 4 objective) assessment. On high-power examination, the round cells contained nuclei that were 4 to 6 times the size of background lymphocyte nuclei (Figs. 3A, B) . More importantly, the nuclei exhibited an irregular membrane with angulated contour. In contrast, the nuclei of JAZF1-rearranged ESS were generally smaller in size (2 to 4 times the size of background lymphocyte nuclei), and all displayed a smooth nuclear contour (Figs. 3C, D) . The chromatin was finely granular to slightly vesicular in appearance without prominent nucleoli. In a subset of tumors the cells were less cohesive, displaying a pseudoglandular or pseudopapillary architecture (Fig. 4A) . Focal sex-cord-like differentiation was present in the round cell area of 2 tumors (Fig. 4B) . A high mitotic rate (> 10/ 10 HPF, up to 77/10 HPF) was seen in 10 of 11 primary uterine and 2 of 3 metastatic tumors; no atypical mitotic figures were identified. Tumor necrosis was present in 10 of 11 primary tumors, and it ranged from multifocal patchy necrosis to extensive geographic necrosis. Mitotic rate in 11 JAZF1-rearranged ESS cases ranged from 1 to 8 MF/10 HPF with an average of 3 MF/10 HPF; only 2 showed > 5 MF/10 HPF. Focal tumor necrosis was seen in 5 cases. The difference in the histologic appearance of YWHAE-FAM22 ESS and JAZF1-rearranged ESS has been summarized in Table 3 .
The spindle cell component was closely juxtaposed to the round cell component in the 7 cases with mixed round and spindle cell areas (Figs. 4C, D) . It showed low to intermediate cellularity and consisted of a proliferation of monomorphic cytologically bland spindle cells embedded in a fibrocollagenous to fibromyxoid matrix (Figs. 4E, F) . The nuclei were ovoid to oblong in shape but had more pointed ends (in comparison with myometrial smooth muscle cells), and the chromatin was finely dispersed with no discernible nucleoli. These spindle cells were arranged in loose fascicles in most instances but formed intersecting fascicles closely mimicking a smooth muscle tumor in 2 tumors (smooth muscle actin and desmin negative) (Figs. 4G, H) . Mitotic activity was low (r3 MF/10 HPF).
In the one ESS in which both the primary uterine tumor and the subsequent pulmonary metastasis were available for review (both demonstrating the YWHAE rearrangement), the uterine tumor that was removed in a piece-meal manner in a supracervical hysterectomy showed spindle morphology with low-grade nuclear features, low mitotic rate (3 MF/10 HPF), and no tumor necrosis. The pulmonary metastasis that developed a year later showed mixed high-grade round cell and low-grade spindle cell components, with the spindle cell area encircling the round cell area. The round cell component consists of cohesive nests of tumor cells with either scanty or moderate amounts of cytoplasm and focally discohesive pseudopapillary areas. In contrast to the uterine primary, the round cell component of the metastatic tumor demonstrated considerably higher mitotic rate (up to 58 MF/10 HPF).
In 2 additional cases, only metastatic tumor was available for review, corresponding to vaginal and pulmonary metastasis, respectively. In the first case, the tumor in the vagina was composed of spindle cells with a small amount of pale cytoplasm, low-grade nuclear features, and infrequent mitoses (1/10 HPF). The pulmonary metastasis consisted of purely high-grade round cells with focal rhabdoid features and displayed a high mitotic (19 MF/10 HPF) rate with focal tumor necrosis.
Immunophenotypic Features of YWHAE-FAM22 ESS
The immunoprofile of the 13 YWHAE-FAM22 ESS cases is summarized in Table 2 . Of the 11 uterine tumors, tumor cells in the round cell component were all CD10 negative; 3 were also ER and PR negative. Minimal (< 5%) weak to moderate ER or PR staining within the round cell areas was seen in 7 tumors, particularly in cells of perivascular location. In contrast, the spindle cell component in all tumors was always diffusely and strongly CD10, ER, and PR positive (Figs. 4H, 5A-C) . There was no difference in the patterns of staining for CD10, ER, and PR between the primary and metastatic tumors. Ki-67 proliferation index was examined in 4 YWHAE-FAM22 ESS cases (cases 1, 2, 3, and 5), and the round cell component showed 24%, 16%, 28%, and 32% proliferation indices, respectively (Fig. 5D ). The spindle cell component present showed < 1% Ki-67 proliferation index. In addition, on the basis of the panel of immunomarkers used for staining by the original sign-out pathologists, the round cell component, including the pseudoglandular and pseudopapillary foci, was consistently negative for epithelial (4), smooth muscle (8), or melanocytic markers (3). The spindle cell component (including areas closely mimicking smooth muscle) was negative for smooth muscle actin, desmin, and caldesmon (5). ER, PR, CD10, and Ki-67 staining was evaluated in 10 JAZF1-rearranged ESS cases with available material. ER was positive in 9 of 10, PR in 8 of 10, and CD10 in 7 of 10 cases, with the staining being usually diffuse and strong in the positive cases. Ki-67 labeling index ranged from < 1% to 8% (average of 3%) (Fig. 5E ).
Karyotypes of YWHAE-FAM22 ESS
Cytogenetic analysis was performed on 9 of the 13 YWHAE-FAM22 ESS, and the results are summarized in Table 1 . All 9 cases displayed t(10;17)(q22;p13) as the main cytogenetic aberration (Fig. 6 ).
DISCUSSION
ESS is currently defined as a neoplasm composed of cells resembling proliferative-phase endometrial stroma that infiltrates the surrounding myometrium in a characteristic "finger-like" permeative manner and typically invades lymphatic or vascular spaces. 14 Implicit in the current WHO definition is the requirement that ESS demonstrate a "highly differentiated" (ie, close resemblance to non-neoplastic endometrial stroma) morphologic appearance. In the past, tumors that had the appearance of proliferative-phase endometrial stroma but had mitotic activity that exceeded 10 mitoses/10 HPF were classified as "high-grade ESS"; however, as normal endometrial stroma can exhibit significant mitotic activity, particularly in its proliferative phase, it is currently accepted that classic "low-grade" ESS should not be classified as "highgrade" on the basis of mitotic activity alone. 8 Therefore, the current WHO classification scheme recognizes 2 As illustrated in our series, although both YWHAE-FAM22 ESS and JAZF1-reararranged ESS show a similar infiltrative pattern through the uterine wall, the former typically exhibits histologically distinctive features that allow its recognition and separation from the latter. In fact, most tumors were diagnosed by the original diagnostician as UES or high-grade uterine sarcoma, and in cases in which the diagnosis of ESS was rendered they were usually additionally qualified as high-grade ESS or ESS with high-grade areas/features. In the single case in which sections of the primary uterine tumor showed only low-grade spindle/ovoid cell morphology in a fibrous matrix, the patient developed pulmonary metastasis a year later, and the metastatic tumor exhibited admixed high-grade round cell and low-grade spindle cell areas. As the uterine tumor was removed in a piece-meal manner in a supracervical hysterectomy procedure with 7 representative sections submitted, it is plausible that a high-grade round cell component was present but not sampled in the hysterectomy specimen, particularly as all other primary uterine tumors examined to date contained a high-grade round cell component. In contrast to JAZF1-rearranged ESS, in which tumors are typically positive for ER, PR, and CD10, immunostaining in YWHAE-FAM22 ESS for ER and PR was focal ( < 5%) in the round cell component, and CD10 immunostaining was consistently negative. This suggests that hormonal therapy may be less effective against YWHAE-FAM22 ESS compared with JAZF1-rearranged ESS. Most YWHAE-FAM22 ESS cases also had a lowgrade spindle cell component that morphologically resembled the fibrous variant of ESS and consistently had diffuse ER, PR, and CD10 immunoreactivity but were negative for muscle markers. This profile is similar to what has been reported for the fibrous variant of ESS, in which CD10 immunoreactivity was detected in the fibroblastic component in 3 of 5 tumors, and smooth muscle markers (caldesmon and desmin) were negative. 41 Not surprisingly, the reported immunophenotype for UES has shown variable positivity for these markers as it likely represents a heterogenous population of entities that are not readily classifiable. In fact, the diagnosis of UES should only be considered after exclusion of a poorly differentiated carcinoma, leiomyosarcoma, and carcinosarcoma, all of which may be morphologically similar in appearance. For UES, CD10, ER, and PR, immunoreactivity has been observed in 51% (22/43), 27% (3/11), and 27% (3/11) of tumors examined, respectively. 11, 1, 17, 26, 40 It is important to note that the endothelial cells of the stromal capillary network can show weak CD10 immunoreactivity and that many of the ESS cases can contain entrapped myometrial smooth muscle that is immunoreactive for muscle markers; hence, positive staining of these non-neoplastic constituents needs to be excluded when interpreting the immunostaining results.
Among adult mesenchymal and mixed epithelial/ mesenchymal tumors, YWHAE-FAM22 rearrangement is specific for ESS. We recently evaluated the specificity of YWHAE-FAM22 rearrangement in a series of 40 different adult gynecologic and nongynecologic mesenchymal or mixed epithelial/mesenchymal neoplasms, including uterine leiomyoma, leiomyosarcoma, adenosarcoma, carcinosarcoma, and UES (with nuclear pleomorphism). 23 Aside from ESS, YWHAE-FAM22 genetic rearrangement was not identified in other adult tumor types examined. Furthermore, YWHAE rearrangement and JAZF1 rearrangement were mutually exclusive.
With regard to tumor nomenclature, we believe that these YWHAE-FAM22 uterine sarcomas should be categorized as ESS because: (1) all YWHAE-FAM22 uterine tumors had extensive permeative growth through the myometrium with vascular invasion, similar to that seen in classic low-grade ESS; (2) all YWHAE-FAM22 ESS also displayed features of established histologic variants of ESS, namely, those with fibromyxoid and sex-cord-like differentiation; and (3) the low-grade spindle cell component exhibited an immunophenotypic characteristic of endometrial stroma, being positive for ER, PR, and CD10, while lacking immunophenotypic evidence for smooth muscle, perivascular epithelioid cell, or epithelial differentiation, whereas the higher-grade component lost expression of these markers. In addition, even though YWHAE-FAM22 ESS exhibits higher-grade nuclear features compared with JAZF1-rearranged ESS, it does not display marked nuclear pleomorphism (< 3 to 1 variation in nuclear size), which distinguishes it from most UESs. As for the proposed terminology of undifferentiated endometrial sarcoma with nuclear uniformity (UES-U) proposed by Kurihara et al, 20 a subset of the 7 UES-U cases described in their series may represent YWHAE-FAM22 ESS; 1 represented a JAZF1-rearranged ESS with classic low-grade ESS component and an apparently transformed high-grade component (ie, dedifferentiation). However, there were no differences in disease prognosis/ behavior between UES-U and undifferentiated endometrial sarcoma with nuclear pleomorphism (UES-P). In contrast to the UES-P, in which 3 of the 5 patients died of the disease (within 3 y after disease diagnosis), or the UES-U, in which 4 of the 7 patients died of disease (all within 1½ y after disease diagnosis), 20 it is evident that YWHAE-FAM22 ESS as shown in the current series does not behave in such an aggressive manner. We therefore do not favor the use of UES-U terminology, particularly as the series described was small in size (n = 7) and genetically heterogenous. More importantly, YWHAE-FAM22 ESS is not truly undifferentiated as it frequently contains a better differentiated low-grade spindle cell component that recapitulates the immunophenotype of endometrial stroma.
We believe that the current evidence indicates that YWHAE-FAM22 ESS is intermediate between JAZF1-rearranged ESS and UES (ie, with nuclear pleomorphism) in terms of malignant potential. We thereby propose a revised classification for uterine sarcomas on the basis of the improved genetic understanding (Fig. 7 ). An overlap between low-grade ESS and high-grade ESS is indicated in the Venn diagram because YWHAE-FAM22 can contain a low-grade spindle cell component, which shares morphologic overlap with the low-grade fibrous or fibromyxoid variant of ESS. 33, 41 Although it is plausible that some of the previously described fibrous/fibromyxoid ESS cases were YWHAE-FAM22 ESS, none of these cases were reported to have an accompanying high-grade component, and the mitotic activity was generally low ( < 10 MF/10 HPF). It therefore appears likely that at least a subset of the fibrous/fibromyxoid variant of ESS reported is genetically distinct from YWHAE-FAM22 ESS. Diagnostically, we recommend the use of FISH or RT-PCR studies to confirm the presence of YWHAE-FAM22 genetic fusion for all nonpleomorphic uterine sarcomas showing either: (1) a biphasic growth pattern with high-grade round cell component and low-grade spindle cell component; (2) purely round cell morphology that is histologically high grade; or (3) purely low-grade spindle cell morphology in a fibrous or fibromyxoid matrix. More importantly, adequate tumor tissue sampling in a resection specimen should be performed, particularly if only low-grade fibrous/fibromyxoid spindle cell morphology is observed.
An intriguing parallel to the t(10;17)(q22;p13)-induced YWHAE-FAM22 genetic fusion seen in ESS is the identical recurrent translocation reported in clear cell sarcoma of the kidney. 6, 35, 36 Clear cell sarcoma of the kidney is a rare sarcoma that occurs nearly exclusively in the pediatric age group, virtually all patients being under 5 years of age at presentation. There is a slight male predominance. Although there is no epidemiologic or anatomic overlap between YWHAE-FAM22 ESS and clear cell sarcoma of the kidney, there is a remarkable histologic resemblance between clear cell sarcoma of the kidney and the round cell component of YWHAE-FAM22 ESS, particularly in areas where the round tumor cells possess a moderate amount of cytoplasm. Genetically, YWHAE-FAM22 fusion has been identified recently in the subset of clear cell sarcoma of the kidney with t(10;17). 34 These findings suggest a shared oncogenetic basis in subsets of ESS and clear cell sarcoma of the kidney and provide another example of fusion oncogene mechanisms with transforming activity in different and distinct disease entities. Other examples of mesenchymal oncogene permissiveness include the ETV6-NTRK3 genetic fusion seen in both infantile fibrosarcoma and secretory breast cancer 18, 39 and the TPM3-ALK fusions in inflammatory myofibroblastic tumor and anaplastic large cell lymphoma. 21, 22 In the current study, we provide a detailed description of histologic and immunohistochemical features for YWHAE-FAM22 ESS. These tumors display highgrade (but nonpleomorphic) round cell histology that is immunophenotypically undifferentiated and frequently includes an admixed low-grade spindle cell component with fibrous/fibromyxoid stroma that is positive for ER, PR, and CD10 immunohistochemically. YWHAE-FAM22 ESS represents a clinically aggressive subtype of ESS, and its distinction from usual low-grade ESS with JAZF1 rearrangement is important to guide clinical management.
